Generic Name and Formulations:
Captopril, hydrochlorothiazide; 25mg/15mg, 25mg/25mg, 50mg/15mg, 50mg/25mg; scored tabs.
Various generic manufacturers
- Angiotensin System Inhibitors Improve OS in mRCC
- Photosensitizing Antihypertensive Agents Linked to Lip Cancer in Non-Hispanic Whites
- Angiotensin-Converting Enzyme (ACE) Inhibitors for Hypertension
- Combination Treatments for Hypertension Chart
- Diuretics for Hypertension
Indications for Captopril/Hydrochlorothiazide:
Take 1 hr before meals. As initial therapy: one 25/15 tab daily; adjust at 6 wk intervals. Previously titrated: use same doses as individual components. Usual max 150mg captopril, 50mg hydrochlorothiazide daily.
See full labeling.
Anuria. Sulfonamide allergy. History of ACEI-associated angioedema.
Fetal toxicity may develop: discontinue if pregnancy is detected. Renal or hepatic dysfunction. Salt/volume depletion. CHF. Dialysis (esp. high-flux membrane). Aortic stenosis. Diabetes. Gout. Asthma. Postsympathectomy. Surgery. Monitor electrolytes. Monitor WBCs and renal function in renal and collagen vascular disease. Discontinue if neutropenia, agranulocytosis, angioedema or laryngeal edema occurs. Pregnancy (Cat.D in 2nd and 3rd trimesters). Nursing mothers: not recommended.
Potentiated by antihypertensives. Potentiates tubocurarine. May antagonize sulfonylureas, oral anticoagulants, uricosurics. May be antagonized by NSAIDs, sympathomimetics. May increase digitalis, lithium, insulin, diazoxide toxicity. Hyperkalemia with potassium-sparing diuretics and supplements. Hypokalemia with ACTH, corticosteroids. Orthostatic hypotension may be increased by alcohol, CNS depressants. May interfere with parathyroid, urinary acetone tests.
ACE inhibitor + diuretic.
Neutropenia, agranulocytosis, proteinuria, nephrotic syndrome, orthostatic hypotension, fluid or electrolyte imbalance, rash, GI upset, dysgeusia, hyperglycemia, hyperuricemia, dizziness, headache, cough, pruritus, angioedema, tachycardia, chest pain, jaundice, blurred vision.
Formerly known under the brand name Capozide.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy